81 related articles for article (PubMed ID: 1284590)
1. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening.
Helzlsouer KJ; Newby J; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1992; 1(7):537-40. PubMed ID: 1284590
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening.
Helzsouer KJ; Newby J; Comstock GW
Am J Epidemiol; 2008 Oct; 168(7):841-4. PubMed ID: 18820278
[TBL] [Abstract][Full Text] [Related]
3. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
4. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
6. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
7. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
8. [Detection of cancer of the prostate. A study of 600 cases].
Teillac P; Bron J; Tobolski F; Cussenot O; Lesourd A; Leroy M; Toubert ME; Brocheriou C; Laval-Jeantet M; Le Duc A
Ann Urol (Paris); 1990; 24(1):37-41. PubMed ID: 1690963
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
[TBL] [Abstract][Full Text] [Related]
10. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
[TBL] [Abstract][Full Text] [Related]
11. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.
Shim HB; Lee SE; Park HK; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(3):250-5. PubMed ID: 17297501
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer: who to screen, and what the results mean.
Small EJ
Geriatrics; 1993 Dec; 48(12):28-30, 35-8. PubMed ID: 7504646
[TBL] [Abstract][Full Text] [Related]
13. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
14. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
15. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
Kuller LH; Thomas A; Grandits G; Neaton JD;
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):373-7. PubMed ID: 15006911
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
18. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
19. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
20. Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
Salmasi AH; Wisniewski AB; Novak TE; Gearhart JP; Migeon CJ; Lakshmanan Y
J Urol; 2008 Oct; 180(4):1422-5; discussion 1425-6. PubMed ID: 18710761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
